XML 49 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stockholders’ Equity (Tables)
12 Months Ended
Dec. 29, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Allocated Employee Stock-Based Compensation Expense
We allocated the stock-based compensation expense for our equity incentive plans and our ESPP as follows (in thousands):
 
Year Ended December 31,
 
202320222021
Research and development$34,320 $45,350 $46,654 
Selling, general and administrative72,025 62,224 73,166 
Total stock-based compensation expense$106,345 $107,574 $119,820 
 
Year Ended December 31,
 
202320222021
Stock options$7,771 $12,790 $19,048 
Restricted stock units70,462 69,775 53,629 
Performance stock units23,938 21,616 43,428 
ESPP4,174 3,393 3,715 
Total stock-based compensation expense$106,345 $107,574 $119,820 
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:
 
Year Ended December 31,
 
202320222021
Stock options$9.45 $8.36 $9.04 
ESPP$4.67 $5.80 $6.12 
Schedule of Fair Value of Employee Share-Based Payments Awards Stock Option Assumptions and Weighted Average Fair Values
The grant-date fair value of stock option grants and ESPP purchases was estimated using the following weighted average assumptions:
 
Year Ended December 31,
 
202320222021
Stock options:
Risk-free interest rate4.14 %2.35 %0.74 %
Dividend yield— %— %— %
Volatility44 %48 %51 %
Expected life5.6 years4.6 years4.6 years
ESPP:
Risk-free interest rate5.07 %1.49 %0.08 %
Dividend yield— %— %— %
Volatility40 %45 %47 %
Expected life6 months6 months6 months
Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values
The grant-date fair value of stock option grants and ESPP purchases was estimated using the following weighted average assumptions:
 
Year Ended December 31,
 
202320222021
Stock options:
Risk-free interest rate4.14 %2.35 %0.74 %
Dividend yield— %— %— %
Volatility44 %48 %51 %
Expected life5.6 years4.6 years4.6 years
ESPP:
Risk-free interest rate5.07 %1.49 %0.08 %
Dividend yield— %— %— %
Volatility40 %45 %47 %
Expected life6 months6 months6 months
Schedule of All Stock Option Activity
Activity for stock options during the year ended December 31, 2023 was as follows (in thousands, except per share amounts):
Shares
Weighted  Average Exercise Price
Weighted Average Remaining Contractual Term
Aggregate Intrinsic Value
Stock options outstanding at December 31, 2022
10,882 $19.49 
Granted357 $20.41 
Exercised(2,340)$12.84 
Cancelled(691)$21.66 
Stock options outstanding at December 31, 2023
8,208 $21.24 2.7 years$24,115 
Stock options exercisable at December 31, 2023
6,981 $21.31 2.3 years$20,207 
Schedule of All RSU Activity Activity for RSUs during the year ended December 31, 2023 was as follows (in thousands, except per share amounts):
Shares
Weighted  Average Grant Date Fair Value
Weighted  Average Remaining Contractual  Term
Aggregate Intrinsic Value
RSUs outstanding at December 31, 2022
11,294 $21.83 
Awarded5,028 $21.65 
Vested and released(2,950)$20.81 
Forfeited(1,498)$21.81 
RSUs outstanding at December 31, 2023
11,874 $22.72 1.7 years$284,856 
Activity for PSUs during the year ended December 31, 2023 was as follows (in thousands, except per share amounts):
Shares
Weighted  Average Grant Date Fair Value
Weighted  Average Remaining Contractual  Term
Aggregate Intrinsic Value
PSUs outstanding at December 31, 2022
4,964 $23.26 
Awarded— $— 
Vested and released(764)$22.48 
Forfeited(309)$24.57 
PSUs outstanding at December 31, 2023
3,891 $23.60 1.3 years$93,351 
Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions
We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $26.05 per share for the 2023 TSR-based RSUs, $33.17 for 2022 TSR-based RSUs and $24.54 for the 2021 PSUs:
2023 TSR-Based RSUs2022 TSR-Based RSUs2021 PSUs
Fair value of Exelixis common stock on grant date
$19.48 $20.70 $21.31 
Expected volatility
40.26 %46.85 %49.21 %
Risk-free interest rate
3.75 %1.59 %0.29 %
Dividend yield
— %— %— %